Nykode Therapeutics ASA (NYKD)

Currency in NOK
1.66
+0.01(+0.30%)
Real-time Data·
NYKD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
High dividend Yield
Fair Value
Day's Range
1.631.68
52 wk Range
1.5512.96
Key Statistics
Prev. Close
1.66
Open
1.65
Day's Range
1.63-1.68
52 wk Range
1.55-12.96
Volume
779.67K
Average Volume (3m)
866.65K
1-Year Change
-86.43%
Book Value / Share
4.31
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NYKD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.75
Upside
+306.63%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Nykode Therapeutics ASA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Nykode Therapeutics ASA Company Profile

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. Nykode Therapeutics AS was founded in 2006 and is headquartered in Oslo, Norway.

Nykode Therapeutics ASA Earnings Call Summary for Q4/2024

  • Q4 2024 revenue tripled to $6.9M, stock up 5.72% despite $6.8M net loss
  • Cash runway extended to Feb 2030, focus on VB1016 and VB10 Neo programs
  • CEO targets $20M annual cost base, notes growing pharma interest in immunotherapy
  • CO3 trial readout expected late 2025, EPS forecast improves for FY2025
  • Strong cash position supports initiatives, but rapid cash burn and sales decline anticipated
Last Updated: 26/02/2025, 14:18
Read Full Transcript

Compare NYKD to Peers and Sector

Metrics to compare
NYKD
Peers
Sector
Relationship
P/E Ratio
−2.1x13.3x−0.5x
PEG Ratio
−0.050.030.00
Price/Book
0.4x4.5x2.6x
Price / LTM Sales
6.4x4.9x3.3x
Upside (Analyst Target)
301.8%63.5%42.8%
Fair Value Upside
Unlock4.7%6.5%Unlock

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.75
(+306.63% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -0.08%
Dividend Yield
60.28%
Industry Median 53.78%
Annualised payout
1.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / -0.23
Revenue / Forecast
137.00K / --
EPS Revisions
Last 90 days

NYKD Income Statement

People Also Watch

124.15
CAPP
-0.12%
12.385
CARR
+0.24%
12.90
OPM
+0.08%
114.85
BESI
-0.39%
111.30
HAUTO
+1.83%

FAQ

What Stock Exchange Does Nykode Therapeutics Trade On?

Nykode Therapeutics is listed and trades on the Oslo Stock Exchange stock exchange.

What Is the Stock Symbol for Nykode Therapeutics?

The stock symbol for Nykode Therapeutics is "NYKD."

What Is the Nykode Therapeutics Market Cap?

As of today, Nykode Therapeutics market cap is 541.74M.

What Is Nykode Therapeutics's Earnings Per Share (TTM)?

The Nykode Therapeutics EPS (TTM) is -0.08.

From a Technical Analysis Perspective, Is NYKD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Nykode Therapeutics Stock Split?

Nykode Therapeutics has split 1 times.

How Many Employees Does Nykode Therapeutics Have?

Nykode Therapeutics has 75 employees.

What is the current trading status of Nykode Therapeutics (NYKD)?

As of 06 Aug 2025, Nykode Therapeutics (NYKD) is trading at a price of 1.66, with a previous close of 1.66. The stock has fluctuated within a day range of 1.63 to 1.68, while its 52-week range spans from 1.55 to 12.96.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.